167 related articles for article (PubMed ID: 18219445)
1. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors.
LoRusso PM; Gadgeel SM; Wozniak A; Barge AJ; Jones HK; DelProposto ZS; DeLuca PA; Evelhoch JL; Boerner SA; Wheeler C
Invest New Drugs; 2008 Apr; 26(2):159-67. PubMed ID: 18219445
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.
Beerepoot LV; Radema SA; Witteveen EO; Thomas T; Wheeler C; Kempin S; Voest EE
J Clin Oncol; 2006 Apr; 24(10):1491-8. PubMed ID: 16574998
[TBL] [Abstract][Full Text] [Related]
3. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
Davis PD; Dougherty GJ; Blakey DC; Galbraith SM; Tozer GM; Holder AL; Naylor MA; Nolan J; Stratford MR; Chaplin DJ; Hill SA
Cancer Res; 2002 Dec; 62(24):7247-53. PubMed ID: 12499266
[TBL] [Abstract][Full Text] [Related]
4. ZD6126: a novel small molecule vascular targeting agent.
Blakey DC; Ashton SE; Westwood FR; Walker M; Ryan AJ
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1497-502. PubMed ID: 12459377
[TBL] [Abstract][Full Text] [Related]
5. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging.
Robinson SP; McIntyre DJ; Checkley D; Tessier JJ; Howe FA; Griffiths JR; Ashton SE; Ryan AJ; Blakey DC; Waterton JC
Br J Cancer; 2003 May; 88(10):1592-7. PubMed ID: 12771928
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
Blakey DC; Westwood FR; Walker M; Hughes GD; Davis PD; Ashton SE; Ryan AJ
Clin Cancer Res; 2002 Jun; 8(6):1974-83. PubMed ID: 12060643
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of high-dose etoposide phosphate in man.
Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
[TBL] [Abstract][Full Text] [Related]
8. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
9. Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma.
Fens MH; Hill KJ; Issa J; Ashton SE; Westwood FR; Blakey DC; Storm G; Ryan AJ; Schiffelers RM
Br J Cancer; 2008 Oct; 99(8):1256-64. PubMed ID: 18797467
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.
Evelhoch JL; LoRusso PM; He Z; DelProposto Z; Polin L; Corbett TH; Langmuir P; Wheeler C; Stone A; Leadbetter J; Ryan AJ; Blakey DC; Waterton JC
Clin Cancer Res; 2004 Jun; 10(11):3650-7. PubMed ID: 15173071
[TBL] [Abstract][Full Text] [Related]
11. Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models.
Kleespies A; Köhl G; Friedrich M; Ryan AJ; Barge A; Jauch KW; Bruns CJ
Neoplasia; 2005 Oct; 7(10):957-66. PubMed ID: 16242078
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days.
Thompson DS; Greco A; Miller AA; Srinivas NR; Igwenezue KB; Hainsworth JD; Schacter LP; Kaul S; Barbhaiya RH; Garrow C
Clin Pharmacol Ther; 1995 May; 57(5):499-507. PubMed ID: 7768072
[TBL] [Abstract][Full Text] [Related]
13. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
Goto H; Yano S; Matsumori Y; Ogawa H; Blakey DC; Sone S
Clin Cancer Res; 2004 Nov; 10(22):7671-6. PubMed ID: 15570000
[TBL] [Abstract][Full Text] [Related]
14. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent.
Micheletti G; Poli M; Borsotti P; Martinelli M; Imberti B; Taraboletti G; Giavazzi R
Cancer Res; 2003 Apr; 63(7):1534-7. PubMed ID: 12670901
[TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126.
Siemann DW; Rojiani AM
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1512-7. PubMed ID: 12459379
[TBL] [Abstract][Full Text] [Related]
16. Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats.
Gould S; Westwood FR; Curwen JO; Ashton SE; Roberts DW; Lovick SC; Ryan AJ
J Natl Cancer Inst; 2007 Nov; 99(22):1724-8. PubMed ID: 18000220
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of etoposide phosphate (etopophos) as a 30-minute infusion on days 1, 3, and 5.
Fields SZ; Igwemezie LN; Kaul S; Schacter LP; Schilder RJ; Litam PP; Himpler BS; McAleer C; Wright J; Barbhaiya RH
Clin Cancer Res; 1995 Jan; 1(1):105-11. PubMed ID: 9815892
[TBL] [Abstract][Full Text] [Related]
18. Potential antagonism of tubulin-binding anticancer agents in combination therapies.
Taraboletti G; Micheletti G; Dossi R; Borsotti P; Martinelli M; Fiordaliso F; Ryan AJ; Giavazzi R
Clin Cancer Res; 2005 Apr; 11(7):2720-6. PubMed ID: 15814654
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.
Raben D; Bianco C; Damiano V; Bianco R; Melisi D; Mignogna C; D'Armiento FP; Cionini L; Bianco AR; Tortora G; Ciardiello F; Bunn P
Mol Cancer Ther; 2004 Aug; 3(8):977-83. PubMed ID: 15299080
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]